Claudia Mertens (MSc) is an animal welfare expert of the SPCA in Zürich and member of two governmental 'Animal Care and Use Committees'. PD Dr. Rülicke is head of the Biological Central Laboratory and expert for transgenic technology at the Institute for Laboratory Animal Sciences University of Zürich, Switzerland. The project was carried out as a 'joint venture' by both authors.
Claudia Mertens firstname.lastname@example.org
PD Dr. Thomas Rülicke email@example.com
Phenotype Characterisation and Welfare Assessment of Transgenic Mice
This project on the assessment of possible adverse biological effects in transgenic mice strains was supported by the 3R Research Foundation. A standardised questionnaire for the characterisation of transgenic mice strains was developed and a set of systematic score sheets created to monitor the health of individual animals at different life-stages on a routine basis. Part of the results will be incorporated into a revised characterisation form to be released by the Federal Veterinary Authorities (Bundesamt für Veterinärwesen) in the near future in Switzerland.
Is there a particular health problem with transgenic animals?
Transgenic mice are valued models in biomedical research.[*] Several strains are used to investigate human congenital diseases; these strains carry a genetic defect that may or may not be clinically apparent in the animals. In practice, altering the genotype has no health consequences for about 90% of transgenic strains, but the remaining 10% have a reduced viability or impaired health at the phenotypic level (2). The impairment is also present even if the animals are not used for experimentation, and is transmitted from one generation to the next by normal breeding. The degree of impairment and the symptoms of suffering will vary (depending on the genetic alteration) from minor to severe and may show up at various stages of life in different strains. Within a single strain, the degree of suffering will depend primarily upon the genetic change and genetic background, but can also be influenced by housing and feeding conditions. It may or may not be possible to alleviate the suffering by specific measures. In any case, each newly created transgenic strain has the potential to cause poor health and suffering in the animals. In this regard, transgenic technology poses a challenge for the 3R goal of 'refinement': if a mouse strain is to carry certain dysfunctions at the genetic level for scientific reasons, everything has to be undertaken to minimise animal suffering.
Can transgenic animals offer a particular contribution to the goals of 3 R?
In spite of the problems listed above, transgenic animals may represent a refinement in comparison to some other traditional experimental models of disease in which the animals bear a heavy load of suffering. It seems possible to create 'elegant' models where - in the best case - a genotype is an excellent model of disease or dysfunction at the molecular or cellular level while the corresponding phenotype is completely healthy. However, in order to ensure that the well-being of a newly created transgenic strain is unaffected, a careful and comprehensive examination is necessary.
Given these two problems and tasks at the level of the animal strain - 1) recognition, prevention, minimisation and therapy of reduced welfare; 2) proof of absence of health problems due to a modified genotype - the first few generations of newly created mutant strains (founders, F1 and F2) need to be characterised with respect to their phenotype using health and welfare assessment guidelines.
What do we have to know about transgenic animals?
The aim of the project was to develop a standardised questionnaire for the characterisation of transgenic strains and a set of systematic score sheets to monitor the health of individual animals at different life-stages on a routine basis.
Forms for a standardised documentation of relevant information
The literature was first reviewed to collect clinical signs described as being useful for recognising health problems and suffering in laboratory animals. This body of literature was then analysed and a relatively large set of parameters selected for the characterisation of transgenic mice. The parameters had to fulfil two criteria: feasible for conducting as a screening test on a routine basis, and indicative of health or animal welfare problems at the strain level.
Next, two standardised forms were developed to characterise transgenic mice comprehensively (1). The form 'Data Record Form' (4, 6) includes 10 different score sheets for litter-wise and individual health monitoring from birth until spontaneous death or euthanasia. This information about individual animals was then structured and evaluated for the health and welfare status of the strain at two levels of detail in the form 'Strain Characterisation' (5, 6): Is there a welfare problem? (Basic Information). If so, give a detailed description of the symptoms (Detail Information; see Table 1 and 2).
Finally, the score sheets were tested for their "user-friendliness" and clarity in a pilot study that monitored and documented 106 mice from two established genetically modified strains in the first three months of life (4). The results demonstrated the fundamental practicality of the protocols, provided that personnel were adequately instructed and able to invest additional time in the monitoring programme.
Table 1 Form for strain characterisation: general structure
Table 2 Form for strain characterisation: basic information (C. Phenotype; overwiew)
Characterisation of transgenic animals improves animal welfare and science as well
A comprehensive characterisation of transgenic mice is indispensable for animal welfare, for the application of the 3R concepts, for the correct interpretation of research results, and for official purposes (annual statistics). The characterisation sheet presented here is feasible for routine use as a standardised procedure. It will contribute to increased scientific accuracy and efficiency in the laboratory. Transgenic animals, whether commercially distributed, transferred to new facilities or used in animal experimentation, should always be accompanied by their score sheet and strain characterisation form. Up to now, a lack of awareness of the problem and a lack of supporting regulations has prevented such a procedure from becoming standardised. However, this will change in the near future: the official characterisation form in use in Switzerland since 1998 (3) is currently under revision and the new version will be much more comprehensive.
Transgenic animals in animal experimentation
Variations from the mean or norm have always been interesting to biomedical research in providing clues as to the normal and pathological functions of living beings. Genetic mutations are particularly useful because they can be reproduced by breeding; thus they are accessible to a thorough investigation. With the advent of transgenic technology and its possibilities of creating large numbers of mutant animals, the generation and use of genetically modified animals has increased dramatically in biomedical and pharmaceutical research and safety testing. In the year 2000, 59'000 such animals - mainly mice - were used for experimentation, an increase of 6.8% over the previous year. In the period 1997 to 2000, about 2600 transgenic mouse strains were being kept in Swiss laboratories. New strains are being added to this number continuously (2).
|Last modified 2008/01/30|